Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential.

[1]  W. Shyu,et al.  Penetration of cefprozil into tonsillar and adenoidal tissues , 1993, Antimicrobial Agents and Chemotherapy.

[2]  W. Shyu,et al.  Oral Absolute Bioavailability and Intravenous Dose‐Proportionality of Cefprozil in Humans , 1992, Journal of clinical pharmacology.

[3]  G. Doern,et al.  In vitro activity of cefprozil (BMY 28100) and cefepime (BMY 28142) against Streptococcus pneumoniae, Branhamella catarrhalis, and Haemophilus influenzae, and provisional interpretive criteria for disk diffusion and dilution susceptibility tests with Haemophilus influenzae. , 1992, Diagnostic microbiology and infectious disease.

[4]  S. Barriere.  Pharmacology and pharmacokinetics of cefprozil. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  A. Leigh,et al.  Safety profile of cefprozil. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Parish Lc,et al.  Cefprozil versus cefaclor in the treatment of mild to moderate skin and skin-structure infections. The Cefprozil Multicenter Study Group. , 1992 .

[7]  J. Venitz,et al.  Excretion of cefprozil into human breast milk , 1992, Antimicrobial Agents and Chemotherapy.

[8]  K. Pittman,et al.  Effect of antacid on the bioavailability of cefprozil , 1992, Antimicrobial Agents and Chemotherapy.

[9]  Ronald N. Jones,et al.  Alternative antimicrobial agents to contemporary treatment of infections cawed by Corynebactaimm parvam ( Propiomibacierimm acmes) , 1992 .

[10]  A. Iravani,et al.  Cefprozil versus cefaclor in the treatment of acute and uncomplicated urinary tract infections. Cefprozil Multicenter Study Group. , 1992, Clinical therapeutics.

[11]  H. Verbrugh,et al.  A noncomparative study of cefprozil at two dose levels in the treatment of acute uncomplicated bacterial sinusitis. , 1992, Clinical therapeutics.

[12]  H. Lode,et al.  Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers , 1992, Antimicrobial Agents and Chemotherapy.

[13]  W. Gooch,et al.  Comparative efficacy and safety of cefprozil and cefaclor in the treatment of acute uncomplicated urinary tract infections. , 1991, The Journal of antimicrobial chemotherapy.

[14]  A. Iravani.  Comparison of cefprozil and cefaclor for treatment of acute urinary tract infections in women , 1991, Antimicrobial Agents and Chemotherapy.

[15]  J. Christenson,et al.  Comparative efficacy and safety of cefprozil (BMY-28100) and cefaclor in the treatment of acute group A beta-hemolytic streptococcal pharyngitis , 1991, Antimicrobial Agents and Chemotherapy.

[16]  J. Blumer,et al.  Comparative trial of cefprozil vs. amoxicillin clavulanate potassium in the treatment of children with acute otitis media with effusion. , 1991, The Pediatric infectious disease journal.

[17]  M. Pichichero,et al.  A comparison of cephalosporins and penicillins in the treatment of Group A beta‐hemolytic streptococcal pharyngitis: a meta‐analysis supporting the concept of microbial copathogenicity , 1991, The Pediatric infectious disease journal.

[18]  K. Pittman,et al.  Pharmacokinetics of Cefprozil in Healthy Subjects and Patients with Hepatic Impairment , 1991, Journal of clinical pharmacology.

[19]  M. Marks,et al.  In-vitro activity of cefprozil (BMY 28100) and loracarbef (LY 163892) against pathogens obtained from middle ear fluid. , 1991, The Journal of antimicrobial chemotherapy.

[20]  A. Bauernfeind.  Comparative antimicrobial spectrum and activity of ceftibuten against clinical isolates from West Germany. , 1991, Diagnostic microbiology and infectious disease.

[21]  J. Nelson,et al.  Pharmacokinetics of cefprozil in infants and children , 1990, Antimicrobial Agents and Chemotherapy.

[22]  J. Hoppe,et al.  In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to six new oral cephalosporins , 1990, Antimicrobial Agents and Chemotherapy.

[23]  K. Pittman,et al.  Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration , 1990, Antimicrobial Agents and Chemotherapy.

[24]  K. Pittman,et al.  Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor , 1990, Antimicrobial Agents and Chemotherapy.

[25]  K. Pittman,et al.  Phase I study of multiple-dose cefprozil and comparison with cefaclor , 1990, Antimicrobial Agents and Chemotherapy.

[26]  K. Nye,et al.  Pharmacokinetics and tissue penetration of cefprozil. , 1990, The Journal of antimicrobial chemotherapy.

[27]  K. Pittman,et al.  Phase I study of single-dose BMY-28100, a new oral cephalosporin , 1990, Antimicrobial Agents and Chemotherapy.

[28]  R. Jones,et al.  BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates. , 1988, Diagnostic microbiology and infectious disease.

[29]  R. Jones,et al.  Disk diffusion susceptibility testing and broth microdilution quality control guidelines for BMY-28100, a new orally administered cephalosporin , 1987, Journal of clinical microbiology.

[30]  H. Kawaguchi,et al.  In vitro and in vivo evaluations of BMY-28100, a new oral cephalosporin. , 1987, The Journal of antibiotics.

[31]  G. Eliopoulos,et al.  In vitro activity of BMY-28100, a new oral cephalosporin , 1987, Antimicrobial Agents and Chemotherapy.

[32]  M. Marks,et al.  In vitro activity of BMY-28100 against common isolates from pediatric infections , 1987, Antimicrobial Agents and Chemotherapy.

[33]  H. Neu,et al.  Comparative antibacterial activity of a new oral cephalosporin, BMY-28100 , 1987, Antimicrobial Agents and Chemotherapy.

[34]  K.,et al.  BMY 28100, a new oral cephalosporin , 1987, Antimicrobial Agents and Chemotherapy.